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Background: Altered expression of serum microRNAs (miRNAs) have been reported to correlate with
carcinogenesis and progression of pancreatic adenocarcinoma (PC), but descriptions of serum exosomal miRNAs in
PC are still lacking. This study was designed to evaluate serum exosomal miRNA levels in PC patients and to
investigate their relationships with clinicopathologic features and prognosis.
Methods: Four miRNAs (miR-17-5p, miR-21, miR-155 and miR-196a) related to PC were selected for examination in
our research. Serum miRNA was examined by RT-PCR in a group of 49 patients, including 22 with PCs, 6 with
benign pancreatic tumors, 7 with ampullary carcinomas, 6 with chronic pancreatitis and 8 healthy participants. The
clinicopathologic data were also collected, and PC patients were classified according to the presence of metastasis,
tumor differentiation and advanced stage.
Results: There were low expressions of exosomal miR-155 and miR-196a in serum samples of PC patients when U-6
was used as a control. Serum exosomal miR-17-5p was higher in PC patients than in non–PC patients and healthy
participants. High levels of miR-17-5p were significantly correlated with metastasis and advanced stage of PC. The
serum exosomal miR-21 level in PC was higher than that in the normal and chronic pancreatitis groups, but was
not significantly correlated with PC differentiation and tumor stage.
Conclusions: There were high expressions of serum exosomal miR-17-5p and miR-21 in PC patients. Examination of
serum exosomal microRNA is a useful serum biomarker for PC diagnosis other than serum-free microRNA. It is
postulated that exosomal miR-17-5p participates in the progression of PC.
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Pancreatic adenocarcinoma (PC) is one of the most
malignant cancers, with an overall 5-year survival rate
of 3% to 6% [1]. In 2010, an estimated 43,140 people were
diagnosed with PC and approximately 36,800 people died
as a result of this disease in the United States, making PC
the fourth-leading cause of cancer-related deaths in men
(after lung, prostate and colorectal cancer) and in women
(after lung, breast and colorectal cancer) [2]. Because
of a lack of improvement in early detection and desirable
treatment strategies, the prognosis of PC patients is* Correspondence: cao@zju.edu.cn
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reproduction in any medium, provided the orextremely poor. Few patients can be cured by surgery [3].
Thus, it is still necessary to search for better diagnostic
biomarkers that accurately represent biological character-
istics of PC, can be used to screen for early-stage PC and
can predict clinical outcomes, which would allow a greater
percentage of patients to undergo curative surgery.
MicroRNAs (miRNAs) are small, noncoding RNAs
about 22 nt in length that regulate gene expression at
the posttranscriptional level and play an important role
in cell proliferation, apoptosis and differentiation [4].
The microRNA database (miRBase release 17.0: http://
www.mirbase.org/) comprises 1,424 human miRNAs to
date [5], many of which were found to correlate with
cancer. Among the 1,424 miRNAs, about 100 associated
with dysregulated expression in PC have been reported. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Details of patients’ clinical information
Category Male Female Total Mean age (yr)
Pancreatic carcinoma 16 6 22 65.3 ± 9.99
Non–pancreatic carcinoma 20 7 27 58.4 ± 13.16
Ampullary carcinoma 5 1 6 40.7 ± 8.99
Benign pancreatic tumor 5 2 7 67 ± 6.19
Chronic pancreatitis 4 2 6 63.8 ± 12.67
Healthy participants 6 2 8 60.3 ± 8.08
Total 31 18 49 61.5 ± 12.22
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better way than that of mRNA to identify cancer type,
because these are more informative during tumor carcino-
genesis, differentiation and progression. Several studies
have recently shown the aberrant expression of serum
miRNAs in PC, which might be useful in early diagnosis of
PC. For instance, Bloomston et al. [7] identified 21 miRNAs
with increased expression and 4 with decreased expression
that correctly differentiated PC from benign pancreatic
tissue. Fifteen overexpressed and eight underexpressed
miRNAs differentiated pancreatic cancer from chronic
pancreatitis (CP). miR-21, which has been well-described
in the literature, has been reported to be strongly over-
expressed in PC and to significantly upregulate PDCD4
expression, thus contributing to cell proliferation and in-
vasion, as well as chemoresistance, in patients with PC [8].
Over the past few years, circulating miRNAs have
emerged as novel biomarkers for detecting cancer and
predicting patients’ prognosis. Despite the findings of
previous researchers that more than 100 miRNAs are
aberrantly expressed in PC [6,7], descriptions of serum
exosomal miRNAs in PC are still lacking, especially
regarding the correlation between serum exosomal
miRNAs and clinicopathologic features of PC, which is
still unknown. In the present study, we examined four
miRNAs in the serum exosome sample. The four miRNAs
have been well-documented to have high expression levels
in the blood of PC patients. We have identified new po-
tential biomarkers for early diagnosis of PC, as well as me-
tastasis and stage prediction. Our results lay the foundation
for the development of serum exosomal miRNAs as novel
biomarkers for PC detection and also raise provocative
questions regarding the potential biological function of
exosomal miRNAs in PC progression.
Methods
Ethics statement
All participants or their guardians gave their written
consent for their serum samples and medical information
to be used for scientific research. The research protocol
was reviewed and approved by the Research Ethics
Committee of Zhejiang University.
Patients and serum samples
Serum samples were collected from the peripheral veins
of 49 patients at the Department of General Surgery,
Second Affiliated Hospital of Zhejiang University School
of Medicine, including 22 patients with PC, 6 with am-
pullary carcinoma (AC), 7 with benign pancreatic tumors
(BPTs), 6 with CP and 8 healthy participants (HP). All the
patients’ serum samples were histologically confirmed,
and the HPs were age- and gender-matched with the PC
group (Table 1). The serum samples were centrifuged at
3,000 rpm for 10 min and then stored at −80°C.Patients were divided into a PC group and a non-PC
group (HPs and patients with AC, BPT or CP). Pathologic
classification was performed according to the International
Union Against Cancer (UICC) and American Joint Com-
mittee on Cancer (AJCC) TNM staging system for PC
established in 2010 [9]. Stages I and II were considered as
early stage and stages III and IV as advanced stage. Patients
were also classified by tumor differentiation and the
presence of metastasis (Table 2). Poorly and poorly to
moderately differentiated pancreatic ductal adenocarcin-
omas (PDACs) were considered as poor differentiation.
Well- and well- to moderately differentiated PDACs were
assigned to the well–differentiated group. The metastatic
conditions of PC were determined on the basis of both
imaging features and intraoperative pathological examin-
ation. We used an observation period of 3 months in the
nonmetastatic patients to exclude potential metastatic
cases.
Isolation of serum exosomal miRNAs
First, 1 ml of serum was filtered through a 0.22-μm filter
(EMD Millipore, Billerica, MA, USA) to remove cell
debris and other cellular organelles, then the filtrate
was ultracentrifugated at 105 g for 1 h twice. Exosomes
were collected from the precipitates, and small RNA was
enriched using the mirVana PARIS RNA isolation kit
(Ambion, Austin, TX, USA) according to the manufac-
turer’s protocol. Briefly, 625 μl of cell disruption buffer
was added to the precipitate. Next, an equal volume of
2× denaturing solution was added and mixed sufficiently
before being mixed with an equal total volume of acid-
phenol:chloroform. A mirVana miRNA column was used
to collect total RNA. The bound RNA was cleaned with the
buffers provided by the manufacturer to remove impurities
and eluted in a final volume of 100 μl.
Screening and verification of circulating miRNAs
by RT-PCR
The serum miRNA profile of PC has been well-described
in several articles. Within the PC-related miRNAs, four
miRNAs (miR-21, miR-17-5p, miR-155 and miR-196a)
were selected as candidate miRNAs, and RNU6B (U6) was
Table 2 Analysis of clinicopathologic features of the primary adenocarcinoma groupa
Category Subcategory Male (n) Female (n) Total (N) Mean age (yr)
TNM stage Early (I and II) 7 2 9 61.3 ± 9.47
Advanced (III and IV) 9 4 13 68.1 ± 9.73
PDAC Poorly differentiated 4 2 6 59.7 ± 11.06
Well-differentiated 12 4 16 67.9 ± 10.80
Metastasis Yes 12 6 18 65.4 ± 10.79
No 4 0 4 64.8 ± 6.24
Total 16 6 22 65.3 ± 9.99
aPDAC = pancreatic ductal adenocarcinoma; TNM = tumor, node, metastasis.
Que et al. World Journal of Surgical Oncology 2013, 11:219 Page 3 of 9
http://www.wjso.com/content/11/1/219used as an endogenous reference. The five randomly
isolated RNAs in the PC group were mixed to examine
the four miRNAs and U6 by reverse transcription polymer-
ase chain reaction (RT-PCR). Expression was considered
low if the cycle threshold (CT) value was 30 or greater.
Dissociation curve analysis was conducted at the end of
PCR cycles to validate the specificity of the expected PCR
product. After that step, the expressed miRNAs were
validated in each sample by RT-PCR.
For miRNA-based RT-PCR assays, Bulge-Loop miRNA
qRT-PCR Primer Sets (one RT primer and a pair of
quantitative PCR primers for each set) specific for miR-21,
miR-17-5p, miR-155 and miR-196a were designed by
RiboBio (Guangzhou, China). Enriched small RNAs (10 μl)
were reverse-transcribed using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems, San Diego,
CA, USA) according to manufacturer’s instructions in a
total reaction volume of 15 μl containing 5 μl of purified
miRNAs, 1.5 μl of 10× RT buffer, 0.15 μl of 100 mM
deoxyribonucleotide triphosphate, 1 μl of reverse tran-
scriptase and 0.19 μl of RNase inhibitor (MultiScribe;
Applied Biosystems), 4.16 μl of RNase-free water and
3 μl of 5× RT primer. This allowed for the creation of a
miRNA cDNA library. Next, a 1:2 dilution of RT products
was used as a template for real-time PCR, which was
carried out on the ABI 7300 Real-Time PCR System
(Applied Biosystems). The 20-μl PCR solution included
10 μl of SYBR Green Master Mix (Life Technologies,
Grand Island, NY, USA), 2 μl of RT product, 2 μl of
universal reverse primer, 2 μl of forward primer and
4 μl of RNase-free water. The reactions were incubated
in a 96-well optical plate at 95°C for 10 min, followed
by 40 cycles at 95°C for 15 s and 60°C for 1 min.
All reactions were run in triplicate. miRNA levels
were quantified by measuring the value of the cycle
threshold change (ΔCT) with U6 as an endogenous
control (ΔCT = mean CTmiRNA – mean CTU6). Rela-
tive expression levels of the miRNAs were expressed as
2–ΔCT. Fold changes of miRNAs between groups were
calculated by the 2−ΔΔCT equation, in which ΔΔCT =
ΔCTsample – ΔCTcontrol.Statistical analysis
All clinicopathologic variables and circulating miRNA
expression levels were analyzed by using PASW Statistics
for Windows software version 18.0 (SPSS, Chicago, IL,
USA). An unpaired t-test was performed to compare the
differences in serum miRNA levels between groups. All
tests were two-sided, and P < 0.05 was considered statisti-
cally significant. Receiver operating characteristic (ROC)
curves were established to evaluate the diagnostic value of
serum miRNAs and discriminate PC patients from HPs
and patients with CP or BPT.Results
Circulating miRNA screening in primary adenocarcinoma
patients
Within the PC-related miRNAs, four miRNAs (miR-21,
miR-17-5p, miR-155 and miR-196a) were selected as
candidate miRNAs, and RNU6B (U6) was used as an
endogenous reference. Fortunately, we found that miR-21,
miR-17-5P and U6 were stably expressed in the serum
exosome of PC patients (CT values = 29.7, 29.4 and 26.6,
respectively), whereas there was low expression of miR-155
and miR-196a (Figures 1 and 2).Increased expression levels of serum exosomal miR-17-5p
and miR-21 in primary adenocarcinoma patients
The ΔCT values of miR-17-5p and miR-21 were 6.27
and 6.61 for PC patients, 7.43 and 7.02 for AC patients,
8.22 and 9.25 for BPT patients, 8.19 and 9.20 for CP
patients and 7.95 and 9.16 for HPs, respectively
(Table 3). The mean levels of miR-17-5p and miR-21
were significantly higher in PC patients than in HPs
and the non-PC group, with 3.16- and 4.05-fold
changes compared with the non-PC group and with
3.2- and 5.86-fold changes compared with HPs (Figure 3).
There was no significant difference in the expression
levels of miR-21 between PC patients and AC patients,
although they tended to be higher in PC patients (6.61
vs. 7.02; P = 0.21).
Figure 1 Reverse transcription polymerase chain reaction amplification curves of microRNAs in serum of patients with pancreatic
adenocarcinoma. U6 (A), miR-17-5p (B) and miR-21 (C) were stably expressed with mean cycle threshold values of 29.7, 29.4 and 26.6,
respectively. miR-155 (D) and miR-196a (E) were found to have low expression levels.
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diagnostic markers of primary adenocarcinoma
ROC curve analyses were performed to evaluate the
diagnostic value of miR-21 and miR-17-5p for PC.
These analyses revealed that the levels of serum
miR-17-5p and miR-21 were potential markers for
discriminating non-PC from PC, with ROC areas
under the curve of 0.887 (95% confidence interval
(CI) = 0.796 to 0.978) and 0.897 (95% CI = 0.803 to
0.991), respectively (Figure 4). At the cutoff values
of 6.826 for miR-17-5p and 7.693 for miR-21, PC
diagnostic sensitivities and specificities were 72.7%and 92.6% for miR-17-5p and 95.5% and 81.5% for
miR-21, respectively (Table 4).
Relationship between miR-17-5p, miR-21 and
clinicopathologic features of primary adenocarcinoma
On the basis of RT-PCR assays of miR-21, we found that
there were 1.23-, 1.28- and 1.13-fold changes among the
different stage, differentiation and metastasis groups of
PC patients (P = 0.339, 0.385 and 0.668, respectively),
indicating no significant correlations with stage, differenti-
ation or metastasis (Figure 5). Circulating miR-17-5p
was significantly elevated in the group of advanced stage
Figure 2 Reverse transcription polymerase chain reaction dissociation curves of microRNAs in sera of patients with pancreatic
adenocarcinoma. Circulating U6 (A), miR-17-5p (B) and miR-21 (C) miRNAs were specifically amplified with a singular peak in the dissociation
curve. The variation in the dissociation curves of miR-155 (D) and miR-196a (E) indicated negative expression.
Table 3 Expression level of circulating miR-17-5p and miR-21a
miR-17-5P miR-21
ΔCT t P ΔCT t P
PC (N = 22) 6.27 ± 1.024 6.61 ± 0.715
Non-PC (N = 27) 7.93 ± 0.784 6.386 <0.001 8.63 ± 1.239 6.781 <0.001
AC (n = 6) 7.43 ± 0.763 2.72 0.011 7.02 ± 0.805 1.27 0.215
BPT (n = 7) 8.22 ± 0.632 4.379 <0.001 9.25 ± 0.832 7.76 <0.001
CP (n = 6) 8.19 ± 0.932 4.119 <0.001 9.20 ± 0.784 7.698 <0.001
HP (n = 8) 7.95 ± 0.705 4.254 <0.001 9.16 ± 0.825 8.298 <0.001
aAC = ampullary carcinoma; BPT = benign pancreatic tumor; CP = chronic pancreatitis; CT = cycle threshold; HP = healthy participant; PC = primary adenocarcinoma.
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Figure 3 Relative expression levels of circulating miR-17-5p and miR-21. miR-17-5p and miR-21 levels were significantly higher in patients
with PC than in healthy participants (HPs) and the non–primary carcinoma (non-PC) group, with 3.16- and 4.05-fold changes compared with the
non-PC group and 3.2- and 5.86-fold changes compared with HPs, respectively.
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and 2.46-fold (P = 0.017) changes, respectively, but it
seems that it did not correlate with tumor differenti-
ation in patients with PDAC (Figure 6). There were eight
(88.9%) of nine and two (15.4%) of thirteen resectable
PC cases in the early stage and advanced stage groups,
respectively (Table 5), indicating that elevated serumFigure 4 Receiver operator characteristic curves of miR-17-5p and mi
characteristic areas under the curve of miR-17-5p and miR-21 were 0.887 (9
0.803 to 0.991), respectively. At the cutoff values of 6.826 for miR-17-5p and
for miR-17-5p and 95.5% and 81.5% for miR-21, respectively.exosomal miR-17-5p was a potential biomarker for
unresectable PC.
Discussion
Early detection of PC remains a challenge for clinical
scientists. More than 80% of patients with PC who were
diagnosed with advanced stage disease could not beR-21 for discriminating non-PC from PC. Receiver operating
5% confidence interval (CI) = 0.796 to 0.978) and 0.897 (95% CI =
7.693 for miR-21, specificities and sensitivities were 72.7% and 92.6%
Table 4 Cycle threshold change values of circulating miR-17-5p and miR-21 predicting primary adenocarcinomaa
miR-17-5P miR-21
≤6.826 >6.826 ≤7.693 >7.693
PC (N = 22) 16 6 21 1
Non-PC (N = 27) 2 25 5 22
χ2 22.3 28.8
OR (95% CI)a 4.6 (2.2 to about 9.6) 18.6 (2.7 to about 127.5)
P value <0.001 <0.001
aCI = confidence limits; OR = odds ratio; PC, primary adenocarcinoma.
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In addition, CP and other BPT (for example, islet cell
tumor, solid pseudopapillary tumor), which present
with clinical and radiologic characteristics similar to
those of PC, such as jaundice, weight loss, elevated
carbohydrate antigen 19-9 (CA 19-9) level and the
presence of diffuse pancreatic enlargement or a focal
pancreatic mass must be distinguished from PC to
avoid unnecessary surgery. Currently available tumor
markers of PC, carcinoembryonic antigen (CEA) and
CA 19-9, exhibit low sensitivity and specificity for PC
diagnosis, and they are particularly unsatisfactory for
early detection of this disease. Although novel blood-
based biomarker discoveries (for example, using proteomic
technologies) have shown promise for cancer detection
[11], new approaches that can complement and im-
prove upon current strategies are still urgently needed.
There are increasing reports of circulating miRNAs as
potential biomarkers for PC detection [12]. Compared
with other large molecules such as mRNA, miRNAs have
been found to be stably expressed in human peripheral
blood and resistant to DNase or RNase activity [13],
whereas mRNA has been found to be rapidly degraded
by RNase A.Figure 5 Relative expression level of circulating miR-21 in each group
1.13-fold changes between the different stage, differentiation and metastas
indicating no significant correlations with stage, differentiation or metastasExosomes, which can be released by many different
cells to the extracellular microenvironment, are small
membrane vesicles of about 60 to 100 nm containing
protein, mRNA and miRNA. Exosomes have been shown
to participate in the immune system by mediating antigen
presentation and transporting miRNA. Previous miRNA
profile studies have suggested that circulating miRNAs are
preferable for cancer detection, including PC [14,15].
However, there is still a lack of serum exosomal miRNA
labeling of PC patients. In this study, we examined four
candidate miRNAs in the serum exosome of PC and
non-PC patients and analyzed the relationships between
the expression levels and clinical pathological features of
disease to assess their clinical application for diagnosing
and monitoring PC. We found that miR-17-5p and miR-21
were significantly elevated in the serum exosome of PC
patients. ROC curve analysis revealed that serum exosomal
miR-21 and miR-17-5p were sensitive biomarkers for
differentiating PC from CP and BPT with high sensitivity
and specificity. Importantly, our data also demonstrate
that higher serum exosomal miR-17-5p was associated
with advanced stage and metastasis of PC, which closely
correlated with the resectability of PC tumors. We believe
that the identification of miR-17-5p may represent a key. On the basis of RT-PCR assay of miR-21, there were 1.23-, 1.28- and
is groups of PC patients (P = 0.339, 0.385 and 0.668, respectively),
is.
Figure 6 Relative expression level of circulating miR-17-5p in each group. Circulating miR-17-5p was significantly higher in the advanced
stage and metastasis groups, with 2.13-fold (P = 0.01) and 2.46-fold (P = 0.017) changes, respectively. No significant difference was found
between the poorly differentiated and well-differentiated groups.
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that have the potential to indicate unresectable PC. Be-
cause serum miR-21 has been reported to be significantly
overexpressed in patients with other types of malignant
tumors, including gastric cancer [15], breast cancer
[16,17], ovarian cancer [18], colon cancer [19] and hepatic
cancer [20], it may not be a specific biomarker for PC
patients.
Apart from the potential of serum exosomal miRNA
levels to aid in clinical diagnosis and prognosis prediction,
this study also revealed some intriguing aspects regarding
their potential function in PC. miR-21 is overexpressed in
various human tissues, including PC [21] and other types
of cancer [22]. In the present study, we also found serum
miR-21 was increased by 5.86-fold in patients with PC
compared with HPs, suggesting that miR-21 is a universal
serum biomarker for several cancers and indicating that
miR-21 may be an important regulatory molecule in car-
cinogenesis. Furthermore, the serum exosomal miR-17-5p
level increased with PC progression, which is consistent
with a previous study of PC tissue [23]. It is questionable
whether serum exosomal miR-17-5p serves as an import-
ant intercellular messenger mediating PC invasion and
metastasis. As the functional roles of miR-17-5p in tumor
biology are unrevealed, we postulate that exosomal miR-
17-5p that predicts a poor prognosis for PC patients mayTable 5 Cross-table of primary adenocarcinoma stage
with resectabilitya
Stage Resectable Unresectable Total
Early stage 8 1 9
Advanced stage 2 11 13
Total 10 12 22
aχ2 = 11.589, P = 0.002.be involved in the inflammatory response or tumor im-
munologic escape via the exosome pathway [24]. Further
studies including a serum exosomal miRNA profile of PC
and function analysis will be performed to explore these
exciting hypotheses.
miRNA assay has a few advantages over conventional
blood-based biomarker examinations such as proteomic
technologies and mRNA assays. (1) Circulating miRNA
expression profiles vary from those in blood cells, some
of which may represent special tissue or cancer origin
[25]. (2) miRNAs were expressed with higher stability in
blood compared with mRNA and protein. Harsh environ-
ments, such as boiling, low or high pH, extended storage
and freeze–thaw cycles, had minimal effect on miRNA
expression levels as measured by RT-PCR [23,26]. (3)
Exosomal miRNAs are abnormally secreted by cancer
cells, and those secreted miRNAs may represent a class of
signaling molecules in mediating intercellular communi-
cation [27]. These advantages show the potential value of
using serum exosomal miRNAs as biomarkers for cancer
detection.Conclusions
Our study demonstrates that serum exosomal miR-17-5p
and miR-21 levels were significantly elevated in PC patients
compared with HPs and non-PC patients, suggesting
that these serum exosomal miRNAs may serve as poten-
tial biomarkers of PC, especially serum miR-17-5p, which
has seldom been reported in other types of cancer, except
for one report in gastric cancer [12]. The relationship
between high levels of miR-17-5p with PC metastasis and
advanced stage encourage us to perform further research
to identify the biological function of exosomal miR-17-5p
as an intercellular messenger mediating PC invasion and
metastasis.
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